COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 6 for:    PRTX-100
Previous Study | Return to List | Next Study

PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02401061
Recruitment Status : Terminated (Enough data has been collected to allow analysis of safety profile and risk-benefit.)
First Posted : March 27, 2015
Last Update Posted : July 5, 2019
Information provided by (Responsible Party):
Protalex, Inc.

Brief Summary:

Pre-clinical and clinical evaluations show that PRTX- 100 has biological activity that may lead to improved platelet levels where these are decreased due to immunological pathologies and that PRTX-100 has an acceptable safety profile. In vivo treatment with PRTX-100 has been shown to raise platelet counts in a mouse model of immune thrombocytopenia (ITP). The primary objective of the study is to assess the efficacy of PRTX-100 in terms of platelet response in patients with chronic/persistent ITP.

Funding Source - FDA OOPD (1R01FD005750-01A1)

Condition or disease Intervention/treatment Phase
Immune Thrombocytopenia Drug: PRTX-100 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia
Study Start Date : September 2015
Actual Primary Completion Date : March 2019
Actual Study Completion Date : June 4, 2019

Arm Intervention/treatment
Experimental: PRTX-100
Patients will be assigned to consecutive PRTX-100 interventions as they are enrolled into the study. Between two and six patients will be enrolled per intervention level. Intervention levels range from one (1) to twenty four (24) micrograms of PRTX-100 per kilogram of patient weight. Patients may receive up to four weekly infusions of PRTX-100 over the study treatment period. PRTX-100 doses ≤ 500 μg will be infused intravenously over 30 minutes. PRTX-100 doses > 500 μg will be infused over 60 minutes. Patients will remain under observation for 4 hours after completion of PRTX-100 dosing for safety management.
Drug: PRTX-100
Four weekly infusions of PRTX-100 at a level of 1 (3, 6,12, 18, or 24) microgram of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation.
Other Names:
  • SpA
  • Staphylococcal Protein A

Primary Outcome Measures :
  1. Platelet Response, Change from Baseline [ Time Frame: Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337 ]
    The primary efficacy endpoint is platelet response defined as a platelet count ≥ 30,000/μL and at least a doubling of baseline platelet count (determined on Day 1 prior to PRTX-100 administration) in patients with a baseline platelet count < 30,000/μL. In patients receiving permitted treatments for ITP with a baseline platelet count ≥ 30,000/μL and < 50,000/μL, an increase in platelet count to ≥ 50,000/μL and at least a doubling of baseline platelet count or an increase to > 100,000/μL be considered a platelet response.

Secondary Outcome Measures :
  1. Complete platelet response, Change from Baseline [ Time Frame: Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337 ]
    Defined as a platelet count ≥ 100,000/μL

  2. Time to platelet response defined as the mean number of days from first PRTX-100 dose until platelet response [ Time Frame: Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337 ]
    The mean number of days from first PRTX-100 dose until platelet response

  3. Durability of platelet response [ Time Frame: Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337 ]
    The number of days from first documented platelet response to first platelet count below platelet response criteria

  4. Concomitant ITP medication use (frequency and amount) [ Time Frame: Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337 ]
    ITP medications include eltrombopag, romiplostim, steroid-sparing adjunctive treatment (e.g. cyclosporine, azathioprine, mycophenolate, danazol, dapsone, or 6-mercaptopurine), and any ITP rescue medications (e.g. IVIG) received during the study Screening and Treatment Periods

  5. Adverse Events [ Time Frame: Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337 ]
    Safety will be described by AEs, SAEs, infusion reactions, clinical laboratory tests (hematology, blood chemistry and urinalysis), vital signs, physical findings and ECGs. AE severity will be graded according to Toxicity Grading Criteria derived from published standards

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Willing and able to provide written informed consent prior to initiation of any study-related procedures
  2. Male or female ≥ 18 years of age
  3. ITP that has persisted for ≥ 3 months. ITP must be diagnosed in accordance The American Society of Hematology 2011 Evidence-based Practice Guideline for Immune Thrombocytopenia (Neunert et al. 2011) or the International Consensus Report on The Investigation and Management of Primary Immune Thrombocytopenia (Provan et al. 2010), as locally applicable.
  4. Received ≥ 1 typical regime for the treatment of ITP. Splenectomy is considered one standard ITP treatment
  5. A mean platelet count of < 30,000/μL, with no individual platelet count > 35,000/μL; or for those subjects receiving a constant dose of permitted treatments for ITP: a mean platelet count < 50,000/μL, with no count greater than 55,000/μL. (Note: The mean platelet count must be determined based on 2 platelet counts including one obtained within ≤ 7 days of first PRTX-100 dose and the other within ≤ 30 days of the first dose of PRTX-100.)
  6. If on corticosteroids, a dose of < 1 mg/kg prednisone per day or equivalent that has been stable for ≥ 21 days prior to the first dose of PRTX-100. High-dose pulse steroid therapy is NOT allowed within 14 days prior to the first dose of PRTX-100.
  7. If receiving eltrombopag or romiplostim, the dose must have been stable for ≥ 21 days prior to the first dose of PRTX-100
  8. If on steroid-sparing adjunctive immunosuppression with cyclosporine, azathioprine, mycophenolate, or 6-mercaptopurine, the dose must have been stable for ≥ 30 days prior to the first dose of PRTX-100 and must be expected to remain stable through study Day 29, unless dose reduction is required due to toxicities. Treatment with other cytotoxic agents (e.g. cyclophosphamide, vincristine) are not allowed within three months prior to the first dose of PRTX- 100.
  9. Any prior treatment with rituximab or any other anti-CD20 agent must have been > 6 months prior to the first dose of PRTX-100
  10. If female, must not be pregnant (pregnancy testing will be performed locally in all female patients of childbearing potential), must not be nursing and must be one of the following:

    • Surgically sterile (bilateral tubal ligation, hysterectomy)
    • Postmenopausal with last natural menses > 24 months prior
    • Premenopausal and using an acceptable form of birth control. Acceptable forms of birth control include: hormonal contraceptives (implantable, oral, patch) used for ≥ 2 months prior to screening or double barrier methods (any combination of two of the following: intrauterine device [IUD], male or female condom with spermicidal gel, diaphragm, sponge, cervical cap). All premenopausal females must have a negative urine or serum pregnancy test at screening and on Day 1 prior to first PRTX-100 treatment.

Exclusion Criteria:

  1. Splenectomy ≤ 90 days prior to the first dose of PRTX-100
  2. Unstable coronary artery disease or other medical condition (such as type 1 diabetes) that, in the Investigator's opinion, might increase the risk to the patient
  3. Evidence of active infection requiring antibiotic therapy ≤ 14 days prior to the first dose of PRTX- 100
  4. Myelodysplastic syndrome. If clinically significant anemia or pancytopenia exists, documentation of a bone marrow aspirate within 24 months prior to the first dose of PRTX-100 showing no evidence of myelodysplasia is required.
  5. Medical history of vasculitis or lupus erythematosus
  6. Propensity to allergic reactions defined as a history of allergic reaction to more than one medication
  7. History of any treatment for cancer within the past two years other than basal cell or squamous cell carcinoma of the skin that has been treated with curative intent
  8. Seropositive for human immunodeficiency virus (HIV)
  9. History of acute/chronic hepatitis B or C and/or carriers of hepatitis B or C (positive for hepatitis B surface antigen or positive anti-hepatitis C antibody test) and evidence of current or active infection (e.g. HCV RNA test)
  10. History suggestive of substance abuse
  11. History or evidence on physical examination or screening laboratory tests of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the study drug
  12. Treatment with IVIG ≤ 14 days prior to the first dose of PRTX-100
  13. Treatment with an anti-Rh D antigen agent (e.g. WinPho) ≤ 14 days prior to the first dose of PRTX-100
  14. Use of any investigational drug, other than eltrombopag or romiplostim, ≤ 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to the first dose of RTX-100
  15. Not willing to stay at the study site for 4 hours after each PRTX-100 infusion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02401061

Layout table for location information
United States, California
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, Michigan
Michigan Center of Medical Research
Farmington Hills, Michigan, United States, 48334
United States, New York
Weil-Cornell Medical College
New York, New York, United States, 10065
United States, Ohio
Gabrail Cancer Center
Canton, Ohio, United States, 44718
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
United Kingdom
Aberdeen Royal Infirmary
Aberdeen, AB, United Kingdom, AB25 27N
Leicester Royal Infirmary
Leicester, Leichester, United Kingdom, LE1 5WW
Queen Elizabeth Hospital
Birmingham, United Kingdom, B15 2TH
Glasgow Royal Infirmary
Glasgow, United Kingdom, G4 0SF
Norfolk and Norwich Hospital
Norwich, United Kingdom, NR4 7UY
Sponsors and Collaborators
Protalex, Inc.
Layout table for investigator information
Study Director: William E Gannon Jr., MD Protalex, Inc.
Layout table for additonal information
Responsible Party: Protalex, Inc. Identifier: NCT02401061    
Other Study ID Numbers: PRTX-100-202
First Posted: March 27, 2015    Key Record Dates
Last Update Posted: July 5, 2019
Last Verified: July 2019
Keywords provided by Protalex, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Purpura, Thrombocytopenic, Idiopathic
Blood Platelet Disorders
Hematologic Diseases
Purpura, Thrombocytopenic
Blood Coagulation Disorders
Thrombotic Microangiopathies
Hemorrhagic Disorders
Autoimmune Diseases
Immune System Diseases
Pathologic Processes
Skin Manifestations
Signs and Symptoms